GLP-1s don't just help you lose weight — they protect your heart. The SELECT trial showed a 20% reduction in heart attacks and strokes, even in people without diabetes.
The SELECT trial (2023) was the first to show cardiovascular benefits of GLP-1s in people with obesity but without diabetes. Semaglutide 2.4mg reduced major adverse cardiovascular events (heart attack, stroke, CV death) by 20% compared to placebo. Benefits appeared within 3 months. This led to FDA approval in March 2024 for cardiovascular risk reduction.
The cardiovascular benefits of GLP-1s go beyond what you'd expect from weight loss alone. They reduce inflammation, improve blood vessel function, and may directly protect heart muscle cells.
Research and analysis on how GLP-1s protect your heart, reduce blood pressure, and improve cardiovascular outcomes.
The landmark trial that proved GLP-1s protect the heart independently of blood sugar.
GuideHow much can you expect your blood pressure to drop? Timeline and mechanisms.
⚡ Research43-51% of patients met disease resolution criteria. Men are 2-3x more likely to have OSA.
⚡ ResearchNew research on semaglutide in heart failure with preserved ejection fraction.
GuideImpact on LDL, HDL, triglycerides — and whether you can reduce statins.
ExplainerWhy the anti-inflammatory effects may matter as much as weight loss.
Compare GLP-1 telehealth providers and find the right fit for your health goals.